Disclosed herein are novel microbial polycultures of two or more cell strains, capable of producinges, flavonoids, and anthocyanidin-3-O-glucosides, and methods of use thereof. Also disclosed is a microbial cell capable of producing phenylpropanoic acids, and methods of use thereof.

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a RRM2 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of a RRM2 gene using said pharmaceutical composition; and methods for inhibiting the expression of RRM2 in a cell.

Disclosed herein are novel microbial polycultures of two or more cell strains, capable of producing flavanones, flavonoids, and anthocyanidin-3-O-glucosides, and methods of use thereof. Also disclosed is a microbial cell capable of producing phenylpropanoic acids, and methods of use thereof.

A method for inhibiting xanthine oxidase and for reducing uric acid levels using a composition obtained by culturing Lactobacillus rhamnosus in a medium. Also disclosed is a composition including a metabolite of Lactobacillus rhamnosus for reducing uric acid levels in a subject and a method for producing the composition.

The present invention relates to a host organism containing recombinant nucleic acids coding for the vitamin K reductase complex subunit 1 (VKORC1) and recombinant nucleic acids coding for a vitamin K dependent (VKD) protein, wherein both the recombinant VKORC1 and the recombinant VKD protein are expressed in said host organism. Further, the present invention relates to a cell culture system comprising cells which contain said recombinant nucleic acids and to methods for improving the productivity of recombinant VKD protein expression in a host organism being cultured in suitable systems.

The disclosure provides polypeptides and encoding nucleic acids of engineered formate dehydrogenases. The disclosure also provides cells expressing an engineered formate dehydrogenase. The disclosure further provides methods for producing a bioderived compound comprising culturing cells expressing an engineered formate dehydrogenase. Where the engineered formate dehydrogenase is capable of catalyzing a conversion.

Provided are an immobilized enzyme and an application thereof in continuous production. The immobilized enzyme is a Polyethyleneimine (PEI)-modified immobilized enzyme, and includes: an enzyme, which includes Amine Dehydrogenase (AmDH) and/or Formate Dehydrogenase (FDH); and a carrier, which is a cyanuric chloride-activated amino carrier. The problem in the prior art of poor performance of an immobilized enzyme is solved, the catalytic activity and reusability of the immobilized enzyme are improved, and the immobilized enzyme is suitable for the field of enzyme immobilization.

There is disclosed a highly stable biocatalytic multi-enzyme system on hydrophobic support for the efficient and continuous hydrogenation of carbon dioxide (CO.sub.2) to formate. The system immobilizes formate dehydrogenase (FDH), glucose dehydrogenase (GDH), and carbonic anhydrase (CA) enzymes on a hydrophobic surface-modified metal-organic framework (MOF), SA-HKUST-1. The hydrophobic surface modification with stearic acid enhances the enzyme stability and reusability, maintaining 95% activity after four cycles. The hydrophobicity of SA-HKUST-1 improves CO.sub.2 diffusion to the immobilized enzymes, significantly boosting the formate production. Enzyme specificity ensures selective reactions, with FDH facilitating CO.sub.2 bioconversion, CA accelerating CO.sub.2 hydration and GDH facilitating cofactor regeneration within the system. The system demonstrates superior performance, producing 255.8 mM formate per gram of MOF per hour. Operating under mild conditions with simple equipment, it reduces costs and eliminates harmful by-products. This invention offers an eco-friendly, sustainable approach for CO.sub.2 mitigation, with potential applications in industrial CO.sub.2 conversion processes.

The present invention relates to a process for the production of polyunsaturated fatty acids in an organism by introducing, into the organism, nucleic acids which encode polypeptides with 5-elongase activity. Advantageously, these nucleic acids can be expressed in the organism together with further nucleic acids which encode polypeptides of the biosynthesis of the fatty acid or lipid metabolism. Especially advantageous are nucleic acids which encode 6-desaturases, 5-desaturases, 4-desaturases and/or 6-elongases. These desaturases and elongases are advantageously derived from Thalassiosira, Euglena or Ostreococcus. The invention furthermore relates to a process for the production of oils and/or triacylglycerides with an elevated content of long-chain polyunsaturated fatty acids, and oils and/or triacylglycerides thus obtained. The invention also relates to the nucleic acids, and constructs, vectors and transgenic organisms comprising the same, as well as oils, lipids and/or fatty acids produced by the process according to the invention and to their use.

Provided herein are compositions and methods directed toward the discovery of improved methods for generating deoxyATP (dATP) in cells that can be delivered to a graft site in the heart to enhance cardiac function.